PRNAF Alterity Therapeutics Ltd (PK)

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2023

 

Alterity Therapeutics Limited

(Name of Registrant)

 

Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  ☒       Form 40-F  ☐

 

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

 

 

 

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

 

The following exhibits are submitted:

 

99.1

Results of Annual General Meeting

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Alterity Therapeutics Limited
	By:	/s/ Geoffrey P. Kempler
		Geoffrey P. Kempler
		Chairman

 

Date: November 29, 2023

  

 

2

 

Exhibit 99.1

 

 

Results of Annual General Meeting

 

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 29 November 2023 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) advises that all resolutions considered at the Annual General Meeting held today were carried by poll.

 

In accordance with ASX Listing rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, details of the proxies received and votes cast in respect of each resolution are attached.

 

Phillip Hains
Company Secretary

 

Alterity Therapeutics Limited ACN 080 699 065
Level 3, 62 Lygon Street Carlton Victoria 3053 Australia
www.alteritytherapeutics.com

 

 

 

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

 

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy’s Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Non-binding resolution to adopt Remuneration Report	Ordinary	80,616,129 76.83%	21,954,866 20.92%	2,360,040 2.25%	14,602,600	89,426,169 80.29%	21,954,866 19.71%	14,602,600	Carried
2 Re-Election of Director Mr. Peter Marks	Ordinary	106,311,290 85.25%	16,351,485 13.11%	2,043,660 1.64%	12,043,800	118,077,176 87.84%	16,351,485 12.16%	12,043,800	Carried
3 Re-Election of Director Mr. Lawrence Gozlan	Ordinary	106,475,730 85.62%	15,842,045 12.74%	2,043,660 1.64%	12,022,800	118,241,616 88.18%	15,842,045 11.82%	12,022,800	Carried
4 Ratification of prior issue of shares (Placement March 2023)	Ordinary	115,193,651 85.81%	17,027,399 12.68%	2,033,660 1.51%	3,043,925	126,949,537 88.17%	17,027,399 11.83%	3,043,925	Carried
5 Approval of 10% Placement Facility	Special	111,296,889 83.43%	19,861,399 14.89%	2,243,660 1.68%	3,896,687	123,262,775 86.12%	19,861,399 13.88%	3,896,687	Carried

 

*

Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

 

 

---